Pfizer moves forward with once-daily version of weight loss pill after setbacks
What is danuglipron's dosing schedule change by Pfizer?
Pfizer has decided to focus on the development of a once-daily formulation of danuglipron, an oral GLP-1 receptor agonist, instead of the previously tested twice-daily version. The decision comes after the company observed encouraging data from an early-stage trial. Pfizer plans to conduct further studies in the second half of the year to evaluate multiple doses of the once-daily formulation.
Why did Pfizer discontinue the twice-daily danuglipron?
Pfizer discontinued the twice-daily danuglipron due to high rates of adverse side effects, including nausea, vomiting, and diarrhea, experienced by patients in the Phase 2b trial4. Over 50% of patients across all dose sizes in the medication group discontinued the medication, leading the company to focus on developing a once-daily version of the drug instead.
What are GLP-1 agonists used for?
GLP-1 agonists are drugs used to treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production6. They mimic the actions of the endogenous incretin hormone GLP-1 that is released by the gut after eating4. These medications help manage blood sugar levels and promote weight loss.